Jefferies analyst David Steinberg says that after meeting with management, he has greater confidence that Pacira Pharmaceuticals' (PCRX) collaboration with Johnson & Johnson (JNJ) offers an opportunity for the company to meaningfully broaden the promotion of Exparel in surgical suites and potentially reaccelerate revenue starting in the second half of 2017. The analyst adds that his sense is the J&J partnership would not stand in the way of any potential takeover. Management did not disclose any stand-still or change of control provisions in its arrangement with J&J, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Pacira with a $53 price target.